thinkpool

The two seminal dates in Humanigen's 2021 YTD history were March 29, and September 9.

On March 29th, the company released the positive topline results of our LIVE-AIR trial.

https://ir.humanigen.com/news/news-details/2021/Humanigen-Reports-Positive-Phase-3Topline-Results-Demonstrating-That-Lenzilumab-Improves-Survival-Without-Need-for-Mechanical-Ventilation-in-Hospitalized-Patients-With-COVID-19/default.aspx

But, unfortunately, also on March 29th, we announced a Public Offering of 5M shares.

https://ir.humanigen.com/news/news-details/2021/Humanigen-Announces-Proposed-Public-Offering-of-Five-Million-Shares-of-Common-Stock/default.aspx

Three weeks later, the net result of these two Press Releases was that we were right back where we started from before the announcements.

The second seminal date, of course, was Sept 9, when we lost half of our value following the FDA's Decline to approve our EUA.

https://ir.humanigen.com/English/news/news-details/2021/FDA-has-declined-Humanigens-Emergency-Use-Authorization-EUA-Request-for-Lenzilumab-in-Hospitalized-COVID-19-Patients/default.aspx

Since then, we have had various announcements regarding rolling reviews and possibly expedited regulatory approval timelines, but what benefit have we achieved? I may be missing something, but it appears to me that regulatory decisions have taken even longer than normal review time, let alone an expedited review time.

We know now that the company is meeting with both US and UK regulators at some time this month. I don't know when either of those meetings are scheduled.

The thing that gives me the greatest assurance of success is hearing Durrant tell us that the company is now "anti-fragile," as he said in the final minute of the Lancet peer review presentation.

That dissuaded me from adding CYDY at $0.99 yesterday. I have long said I would consider a buy at sub-one dollar. However, nor did I add to HGEN in the low 5's yesterday. We'll see how today goes.